Diacylglycerol acyltransferase 1 inhibition with <scp>AZD7687</scp> alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial

Abstract

Altered lipid handling and hormone secretion in the gut were demonstrated during 1-week treatment with the DGAT1 inhibitor AZD7687. However, the apparent lack of therapeutic window owing to GI side effects of AZD7687, particularly diarrhoea, makes the utility of DGAT1 inhibition as a novel treatment for diabetes and obesity questionable.